Prostate cancer multifocality: Impact on cancer biology and treatment recommendations

Panminerva Medica

Volumn 52, Issue 3, 2010, Pages 209-216

  Delacroix, S E ^a   Ward, J F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Prostatic neoplasms, biology; Prostatic neoplasms, diagnosis; Prostatic neoplasms, therapy

Indexed keywords

CATHETER ABLATION; HUMAN; MALE; METASTASIS; PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; REVIEW;

CATHETER ABLATION; HUMANS; MALE; NEOPLASM METASTASIS; PHENOTYPE; PROSTATIC NEOPLASMS;

EID: 79952051162     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al. Mortality results from the Goteborg randomised populationbased prostate-cancer screening trial. Lancet Oncol 2010.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320.
3. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: patterns of change in the era of prostatespecific antigen. World J Urol 1997; 15: 331.
4. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310.
5. Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA. The Epstein Criteria Predict for Organ-Confined But Not Insignificant Disease and a High Likelihood of Cure at Radical Prostatectomy. Eur Urol 2009.
6. Ward JF, Jones, JS. Classification system: organ preserving treatment for prostate cancer. Urology 2010; 75: 1258.
7. Bostwick DG, Waters DJ, Farley ER, Meiers I, RukstalisD, Cavanaugh WA et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007; 70: 42.
8. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60: 264.
9. Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2010.
10. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 2005; 18: 1022.
11. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007; 110: 906.
12. Haggman M, Nordin B, Mattson S, Busch C. Morphometric studies of intra-prostatic volume relationships in localized prostatic cancer. Br J Urol 1997; 80: 612.
13. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395.
14. Epstein JI. An update of the Gleason grading system. J Urol 2010; 183: 433.
15. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007; 4: 632.
16. Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H. Pathologie characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol 2004; 22 :40.
17. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 1: 60.
18. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988; 139: 1235.
19. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998; 90: 233.
20. Cheng L, Bostwick DG, Li G, Wang Q, Hu N, Vortmeyer AO et al. Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer 1999, 85: 2017.
21. Macintosh CA, Stower M, Reid N, Maitland NJ. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998; 58: 23.
22. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 7793.
23. Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW et al. Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. Prostate 2010.
24. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559.
25. Dugan JA, Bostwick, DG, Myers, RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275: 288.
26. Albertsen PC, Hanley JA, Gleason, DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975.
27. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969.
28. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tie) prostate cancer. JAMA 1994; 271: 368.
29. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL. et al. The 'CaP Calculator':an online decision support tool for clinically localized prostate cancer. BJU Int 2010; 105: 1417.
30. Moussa AS, Kattan MW, Berglund R, Yu C, Fareed K, Jones JS. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. BJU Int 2010; 105: 352.
31. Sengupta S, Blute ML. Predictive Models for Prostate Cancer. AUA Update Series, 2006; 25: 8.
32. Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology, V2.2010, 2010.
33. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002; 20: 82.
34. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591.
35. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer:risk assessment and treatment. J Urol 2007; 178: S14.
36. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18: 1164.
37. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy:data from CaPSURE. J Urol 2005; 173: 1126.
38. Dong F, Kattan MW, Steyerberg EW, Jones JS, Stephenson AJ, Schroder FH et al. Validation of pretreatment nomograms for predicting indolent prostate cancer:efficacy in contemporary urological practice. J Urol 2008; 180: 150.
39. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009; 181: 1628.
40. Klotz L. Active surveillance for prostate cancera review. Curr Urol Rep 2010; 11: 165.
41. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC et al. Expectant management of prostate cancer with curative intent:an update of the Johns Hopkins experience. J Urol 2007; 178: 2359.
42. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005; 95: 956.
43. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171: 1520.
44. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112: 2664.
45. Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy. Urology, 2010.
46. Klotz L. Active surveillance for favorable-risk prostate cancer:who, how and why? Nat Clin Pract Oncol 2007; 4: 692.
47. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E et al. Feasibility study:watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664.
48. Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 2009; 104: 490.
49. Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A et al. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology 2009; 73: 1087.
50. Falzarano SM, Zhou M, Hernandez AV, Moussa AS, Jones JS, Magi-Galluzzi C. Can Saturation Biopsy Predict Prostate Cancer Localization in Radical Prostatectomy Specimens:A Correlative Study and Implications for Focal Therapy. Urology, 2010.
51. Jones JS. Saturation biopsy for detecting and characterizing prostate cancer. BJU Int 2007; 99: 1340.
52. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166: 104.
53. Patel AR, Jones JS. Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol 2009; 19: 232.
54. Megwalu II, Ferguson GG, Wei JT, Mouraviev V, Polascik TJ, Taneja S et al. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int 2008; 102: 546.
55. Moussa AS, Meshref, A, Schoenfield L, Masoud A, Abdel-Rahman S, Li J et al. Importance of additional "extreme" anterior apical needle biopsies in the initial detection of prostate cancer. Urology 2010; 75: 1034.